Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TAGAMET HB | MedTech Products | N-020238 OTC | 1996-08-21 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
basic care acid reducer | ANDA | 2022-01-14 |
cimetidine | ANDA | 2025-02-20 |
cimetidine 10% / lidocaine 5% / salicylic acid 40% | unapproved drug other | 2019-04-24 |
cimetidine 200 | ANDA | 2025-03-10 |
cimetidine 5% / ibuprofen 2% / salicylic acid 17% | unapproved drug other | 2019-05-17 |
cimetidine hydrochloride | ANDA | 2025-01-06 |
cimetidine hydrochloride oral solution | ANDA | 2022-10-17 |
equate cimetidine | ANDA | 2022-03-10 |
heartburn prevention | ANDA | 2022-11-14 |
heartburn relief | ANDA | 2022-01-05 |
Code | Description |
---|---|
S0023 | Injection, cimetidine hydrochloride, 300 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bacterial infections | D001424 | — | A49 | 1 | — | — | — | — | 1 |
Drug common name | Cimetidine |
INN | cimetidine |
Description | Cimetidine is a member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach. It has a role as a H2-receptor antagonist, a P450 inhibitor, an anti-ulcer drug, an analgesic and an adjuvant. It is a member of guanidines, a member of imidazoles, an aliphatic sulfide and a nitrile. |
Classification | Small molecule |
Drug class | H2-receptor antagonists (cimetidine type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN/C(=N\CCSCc1nc[nH]c1C)NC#N |
PDB | — |
CAS-ID | 51481-61-9 |
RxCUI | — |
ChEMBL ID | CHEMBL30 |
ChEBI ID | 3699 |
PubChem CID | 2756 |
DrugBank | DB00501 |
UNII ID | 80061L1WGD (ChemIDplus, GSRS) |